Access to Hematopoietic Stem Cell Transplantation in Brazil: facing our challenges.

Hematopoietic Stem Cell Transplantation (HSCT) for all session SBTMO 2023

Authors

  • Vaneuza Araujo Moreira Funke Complexo Hospital de Clínicas -Universidade Federal do Paraná, Serviço de Transplante de Medula Óssea
  • Carmen Bonfim Hospital Pequeno Principe, Curitiba, PR
  • Luiz Guilherme Darrigo Juniro University of Ribeirão Preto- São Paulo
  • Fernando Barroso Duarte Federal University of Ceara

DOI:

https://doi.org/10.46765/2675-374X.2023v4n3p211

Keywords:

HSCT, access, challenges

Abstract

At the Session HSCT for all in SBTMO 2023 the main current challenges for the transplant in Brazil were discussed with panelists an the cordinator of National Transplant System. This article has the objective of reporting the main aspects of the discussion for future actions. Access to beds for adult and pediatric patients, better distribution througout the country, acces to critical medications such as antiviral drugs and imunnessupressors for GVHD phrophylaxis and therapy were discussed. The need for data managers at the centers fostering the transplant data registry was also pointed out. Extension of this discussion among transplant centers and goverment is very important in order to find solutions for improvement in HSCT in Brazil.

Downloads

Published

12/27/2023

How to Cite

Funke, V. A. M., Bonfim, C., Darrigo Juniro, L. G., & Barroso Duarte, F. (2023). Access to Hematopoietic Stem Cell Transplantation in Brazil: facing our challenges. : Hematopoietic Stem Cell Transplantation (HSCT) for all session SBTMO 2023. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 4(3), 211. https://doi.org/10.46765/2675-374X.2023v4n3p211

Issue

Vol. 4 No. 3 (2023): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

Copyright (c) 2023 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)

1 2 > >>